Unknown

Dataset Information

0

A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.


ABSTRACT: Listeria monocytogenes (Lm)-based vaccines stimulate both innate and adaptive immunity. ANZ-100 is a live-attenuated Lm strain (Lm ?actA/?inlB). Uptake by phagocytes in the liver results in local inflammatory responses and activation and recruitment of natural killer (NK) and T cells, in association with increased survival of mice bearing hepatic metastases. The Lm ?actA/?inlB strain, engineered to express human mesothelin (CRS-207), a tumor-associated antigen expressed by a variety of tumors, induces mesothelin-specific T-cell responses against mesothelin-expressing murine tumors. These two phase I studies test ANZ-100 and CRS-207 in subjects with liver metastases and mesothelin-expressing cancers, respectively.A single intravenous injection of ANZ-100 was evaluated in a dose escalation study in subjects with liver metastases. Nine subjects received 1 × 10(6), 3 × 10(7), or 3 × 10(8) colony-forming units (cfu). CRS-207 was evaluated in a dose-escalation study in subjects with mesothelioma, lung, pancreatic, or ovarian cancers. Seventeen subjects received up to 4 doses of 1 × 10(8), 3 × 10(8), 1 × 10(9), or 1 × 10(10) cfu.A single infusion of ANZ-100 was well tolerated to the maximum planned dose. Adverse events included transient laboratory abnormalities and symptoms associated with cytokine release. Multiple infusions of CRS-207 were well tolerated up to 1 × 10(9) cfu, the determined maximum tolerated dose. Immune activation was observed for both ANZ-100 and CRS-207 as measured by serum cytokine/chemokine levels and NK cell activation. In the CRS-207 study, listeriolysin O and mesothelin-specific T-cell responses were detected and 37% of subjects lived ?15 months.ANZ-100 and CRS-207 administration was safe and resulted in immune activation.

SUBMITTER: Le DT 

PROVIDER: S-EPMC3289408 | biostudies-literature | 2012 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.

Le Dung T DT   Brockstedt Dirk G DG   Nir-Paz Ran R   Hampl Johannes J   Mathur Shruti S   Nemunaitis John J   Sterman Daniel H DH   Sterman Daniel H DH   Hassan Raffit R   Lutz Eric E   Moyer Bentley B   Giedlin Martin M   Louis Jana-Lynn JL   Sugar Elizabeth A EA   Pons Alice A   Cox Andrea L AL   Levine Jordana J   Murphy Aimee Luck AL   Illei Peter P   Dubensky Thomas W TW   Eiden Joseph E JE   Jaffee Elizabeth M EM   Laheru Daniel A DA  

Clinical cancer research : an official journal of the American Association for Cancer Research 20111206 3


<h4>Purpose</h4>Listeria monocytogenes (Lm)-based vaccines stimulate both innate and adaptive immunity. ANZ-100 is a live-attenuated Lm strain (Lm ΔactA/ΔinlB). Uptake by phagocytes in the liver results in local inflammatory responses and activation and recruitment of natural killer (NK) and T cells, in association with increased survival of mice bearing hepatic metastases. The Lm ΔactA/ΔinlB strain, engineered to express human mesothelin (CRS-207), a tumor-associated antigen expressed by a vari  ...[more]

Similar Datasets

| S-EPMC8132300 | biostudies-literature
| S-EPMC4397277 | biostudies-literature
| S-EPMC7727397 | biostudies-literature
| S-EPMC8853207 | biostudies-literature
2022-10-27 | PXD031295 | Pride
| S-EPMC7585873 | biostudies-literature
2020-06-30 | GSE149809 | GEO
| S-EPMC9098475 | biostudies-literature
| S-EPMC4718315 | biostudies-other
| S-EPMC1436023 | biostudies-literature